What is Metrion Biosciences?
Metrion Biosciences operates at the intersection of advanced neuroscience and pharmaceutical research, providing essential preclinical services that mitigate risk in drug development. By focusing on high-throughput screening and GLP-compliant hERG testing, the firm addresses some of the most complex challenges in modern pharmacology. Their market position is defined by a commitment to technical excellence, enabling biotech and pharmaceutical clients to navigate the regulatory landscape with greater precision. As a CRO, Metrion serves as an extension of internal R&D teams, offering the specialized infrastructure required to validate drug candidates before they reach clinical trials.
How much funding has Metrion Biosciences raised?
Metrion Biosciences has raised a total of $14.2M across 4 funding rounds:
Grant
$2.5M
Series B
$3.7M
Unspecified
$3.7M
Private Equity
$4.4M
Grant (2016): $2.5M, investors not publicly disclosed
Series B (2021): $3.7M led by Gresham House Asset Management
Unspecified (2021): $3.7M supported by Gresham House Ventures
Private Equity (2023): $4.4M featuring Maven Capital Partners UK and Gresham House Ventures
Key Investors in Metrion Biosciences
Maven Capital Partners UK
Maven Capital Partners UK LLP is a private equity and venture capital firm that focuses on providing growth capital to high-potential businesses, often supporting companies through various stages of their development lifecycle.
Gresham House Asset Management
Gresham House is a specialized asset manager that provides tailored investment solutions across alternative asset classes, including strategic public and private equity, with a focus on delivering sustainable long-term financial returns.
Gresham House Ventures
Gresham House Ventures is a growth-focused investment arm that partners with ambitious management teams to scale innovative businesses, providing both capital and strategic guidance to drive long-term value creation.
What's next for Metrion Biosciences?
With the recent influx of capital, Metrion Biosciences is poised to scale its operational capacity and expand its suite of integrated drug discovery services. The strategic focus will likely involve enhancing high-throughput screening capabilities and deepening expertise in cardiac safety, areas that remain high-priority for global pharmaceutical firms. By leveraging this latest financing, the company aims to solidify its reputation as a premier partner for complex ion channel research, potentially exploring new therapeutic modalities and expanding its footprint in the international drug discovery market. The firm's ability to maintain long-term partnerships with institutional investors suggests a stable outlook for future innovation and service expansion.
See full Metrion Biosciences company page
